Rahul Bhargava, Director and Head of Hematology, Hematocology, and Stem Cell Transplant at Fortis Health Care, shared a post on LinkedIn:
“69-year-old AML patient on Azacitidine – thriving at 4 years!
This is not luck – this is science meeting perseverance.
Translational research is unlocking disease pathways, leading to new therapies that extend lives.
NGS MRD is now a clinical reality, enabling precise monitoring at the molecular level.
With the right place, right tools, and dedicated teams, what once seemed distant is now within reach.
We are living in an era where innovation is rewriting outcomes. The journey continues.
Anusha S., Aastha Gupta, Nikhil M Kumar, Rachit Agrawal, Dr. Neha Rastogi Panda, and Shrinidhi Nathany, who have made NGS MRD possible in India. Kudos to you and your team, Centre of Excellence for Acute Leukemias.”
More posts featuring Rahul Bhargava on OncoDaily.
